Form 4: Freda Lewis-Hall Acquires Stock Options in Pyxis Oncology

Director Freda Lewis-Hall acquired stock options in Pyxis Oncology, Inc. on March 31, 2025.

Summary

• Freda Lewis-Hall, a director of Pyxis Oncology, Inc., reported a transaction on March 31, 2025.
• She acquired stock options (right to buy) for 36,979 shares of common stock at an exercise price of $0.98 per share.
• These options vest 100% on the first anniversary of the grant date, contingent upon continued service.
• Following the transaction, Lewis-Hall directly owns 36,979 derivative securities.

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a standard disclosure of stock option grants. The vesting schedule suggests a commitment from the director.

Positives

• The acquisition of stock options by a director signals confidence in the company's future performance.

Future Outlook

The document does not contain specific forward-looking statements, but the vesting of the options is contingent on continued service, suggesting an expectation of ongoing involvement.

Industry Context

This is a standard disclosure related to insider transactions, common in publicly traded companies. It provides transparency regarding the holdings and transactions of company insiders.

Stakeholder Impact

• The transaction provides transparency to shareholders regarding insider activity.
• Employees may view the stock option grant as a positive sign of management's commitment.

Key Dates

Keywords

Stock Options, Form 4, Beneficial Ownership, Pyxis Oncology, Lewis-Hall, Director, PYXS